Literature DB >> 23959597

High level of HIV-2 false positivity in KwaZulu-Natal province: a region of South Africa with a very high HIV-1 subtype C prevalence.

Lavanya Singh1, Raveen Parboosing, Justen Manasa, Pravi Moodley, Tulio de Oliveira.   

Abstract

Human immunodeficiency virus 2 (HIV-2) is found predominantly in West Africa. It is not unlikely, however, that HIV-2 may also be found in South Africa, due to the influx of immigrants into this country. It is important to distinguish between HIV-1 and HIV-2 since the clinical courses and treatment responses of these viruses are different. Routine serological methods for diagnosing HIV do not differentiate between HIV-1 and -2 infections, while rapid tests, viral load quantification and PCR are HIV-type--specific. The objective of this study was to describe the seroprevalence and molecular epidemiology of HIV-2 in KwaZulu-Natal, one of the regions with the highest HIV prevalence in the world and home of the two largest harbors in South Africa. HIV-1 positive samples were screened for antibodies against HIV-2, using a rapid test. The confirmation of HIV-2 positive samples was done by PCR. Of the 2,123 samples screened, 319 (15%) were identified as positive by the rapid test. None of these samples were confirmed positive by PCR. To explore this discrepancy in the results, a subset (n = 52) of the rapid HIV-2 positive samples was subjected to Western blotting. Thirty-seven (71%) of these were positive, yielding an overall HIV-2 seroprevalence of 10.6%. Three out of 28 (10.7%) Western blot positive samples were positive by a Pepti-LAV assay. This discrepancy between serological and molecular confirmation may be attributed to non-specific or cross-reacting antibodies. The use of rapid tests and Western blots for HIV-2 diagnosis in South Africa should be interpreted with caution.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  HIV-2; South Africa; diagnosis; prevalence; serology

Mesh:

Year:  2013        PMID: 23959597     DOI: 10.1002/jmv.23716

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

1.  Early Diagnosis of HIV-1 and HIV-2 Using Cobas HIV-1/HIV-2 Qualitative Test: A Novel Qualitative Nucleic Acid Amplification Test for Plasma, Serum, and Dried Blood Spot Specimens.

Authors:  Lucia Hans; Nicole von Allmen; Anke Edelmann; Jörg Hofmann; Alex Y Nilsson; Christian O Simon; Britta Seiverth; Peter Gohl; Sergio Carmona
Journal:  J Acquir Immune Defic Syndr       Date:  2021-08-15       Impact factor: 3.771

2.  HIV-1/2 differentiation in a South African public laboratory.

Authors:  Rendani T Mafuyeka; Lynne M Webber; Piet Becker; Simnikiwe H Mayaphi
Journal:  South Afr J HIV Med       Date:  2021-03-12       Impact factor: 2.744

3.  An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in Nigeria.

Authors:  Ogbonnaya S Njoku; Mark M Manak; Robert J O'Connell; Ashley L W Shutt; Jennifer A Malia; Richard A Heipertz; Sodsai Tovanabutra; Mark J Milazzo; Gideon Akindiran Akintunde; Abraham S Alabi; Aminu Suleiman; Amos A Ogundeji; Terfa S Kene; Robbie Nelson; Ojor R Ayemoba; Darrell E Singer; Merlin L Robb; Sheila A Peel; Nelson L Michael
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

4.  Does antiretroviral therapy use affect the accuracy of HIV rapid diagnostic assays? Experience from a demographic health and surveillance site in rural South Africa.

Authors:  Mark J Siedner; Kathy Baisley; Olivier Koole; Innocentia Mpofana; Gregory Ording-Jespersen; Philippa Matthews; Kobus Herbst; Theresa Smit; Deenan Pillay
Journal:  Diagn Microbiol Infect Dis       Date:  2020-03-02       Impact factor: 2.803

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.